Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.73
-0.03 (-0.39%)
Aug 29, 2025, 4:00 PM - Market closed
Arvinas Employees
Arvinas had 430 employees as of December 31, 2024. The number of employees decreased by 15 or -3.37% compared to the previous year.
Employees
430
Change (1Y)
-15
Growth (1Y)
-3.37%
Revenue / Employee
$866,977
Profits / Employee
-$168,837
Market Cap
567.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | 179 | 46 | 34.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARVN News
- 1 day ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 24 days ago - Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 7 weeks ago - Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - GlobeNewsWire
- 2 months ago - Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewsWire
- 3 months ago - Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - GlobeNewsWire